Literature DB >> 21472497

Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies.

Brian Healy1, Tanuja Chitnis, David Engler.   

Abstract

In patients with multiple sclerosis, investigation of a treatment effect on disease progression in clinical trials and observational studies often uses sustained progression on the expanded disability status scale (EDSS) as an outcome. It is not clear whether this outcome is the most powerful to detect a treatment effect on clinical disease progression. Assessment of EDSS modeling choice on the detection of treatment effect was of interest. This assessment was separately conducted under three potential treatment effects: treatment reducing the chance of higher future EDSS, treatment increasing the chance of lower future EDSS, and treatment leading to both effects. To assess the effect of modeling choice, nine modeling strategies were applied to the data to determine the most powerful approach. EDSS measurements were simulated at 6 month intervals for 24 months. Each patient's initial EDSS value ranged between 0 and 3, and probabilities of transitioning from one EDSS state to another were based on the empirical probabilities of transition obtained from available clinical data. Modeling approaches based on sustained progression had less power than approaches which modeled the EDSS score directly, regardless of treatment effect. This difference was especially pronounced when the treatment effect corresponded to an increase in the probability of improvement. Sustained progression on the EDSS is a less powerful outcome measure for clinical progression than approaches based on the actual EDSS values.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472497     DOI: 10.1007/s00415-011-6021-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

1.  Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties.

Authors:  Yan D Zhao; Dewi Rahardja; Yongming Qu
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

2.  Disability as an outcome in MS clinical trials.

Authors:  G C Ebers; L Heigenhauser; M Daumer; C Lederer; J H Noseworthy
Journal:  Neurology       Date:  2008-05-14       Impact factor: 9.910

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

Authors:  D K Li; D W Paty
Journal:  Ann Neurol       Date:  1999-08       Impact factor: 10.422

5.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

6.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Authors:  D W Paty; D K Li
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

Authors:  Mark P Gorman; Brian C Healy; Mariann Polgar-Turcsanyi; Tanuja Chitnis
Journal:  Arch Neurol       Date:  2009-01

9.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

View more
  7 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  A unified framework for the comparison of treatments with ordinal responses.

Authors:  Tong-Yu Lu; Wai-Yin Poon; Siu Hung Cheung
Journal:  Psychometrika       Date:  2013-11-28       Impact factor: 2.500

3.  Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.

Authors:  A M Novakovic; E H J Krekels; A Munafo; S Ueckert; M O Karlsson
Journal:  AAPS J       Date:  2016-09-15       Impact factor: 4.009

Review 4.  Interferon beta and glatiramer acetate therapy.

Authors:  Corey A McGraw; Fred D Lublin
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.

Authors:  Brian C Healy; Bonnie I Glanz; Elyse Swallow; James Signorovitch; Kaitlin Hagan; Diego Silva; Corey Pelletier; Tanuja Chitnis; Howard Weiner
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-04-11

Review 6.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

7.  Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany.

Authors:  Thomas Henze; Sylvia von Mackensen; Gerald Lehrieder; Uwe K Zettl; Carmen Pfiffner; Peter Flachenecker
Journal:  Health Qual Life Outcomes       Date:  2014-08-01       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.